BioNTech has acquired Neon Therapeutics in an all stock transaction valued at $2.18...
- BioNTech acquires T cell therapy-focused Neon for $67m
- NICE cancer guidance: good news for Ibrance and Lynparza
- FDA grants Clovis’ Rubraca fast track designation for prostate cancer
- Japan approves ViiV’s two drug regimen Dovato for HIV
- MorphoSys and Incyte sign $900m deal for B-cell malignancies drug
UK NICE says more data required to approve Bayer’s Vitrakvi
The National Institute for Health and Care Excellence (NICE) in the UK has not recommended Bayer’s cancer drug Vitrakvi (larotrectinib) for routine use on the National Health Service (NHS).
BioNTech acquires T cell therapy-focused Neon for $67m
BioNTech has acquired Neon Therapeutics in an all stock transaction valued at $2.18 per share or approximately $67m. According to the terms of the deal, Neon will be merged with ENDOR Lights, a wholly owned subsidiary of BioNTech.
Novo Nordisk secures FDA expanded indication for Ozempic
The US Food and Drug Administration (FDA) has approved a new indication for Novo Nordisk’s Ozempic (semaglutide).
NICE cancer guidance: good news for Ibrance and Lynparza
The UK’s pricing regulator NICE decides whether new therapies are sufficiently cost-effective for NHS use. In its most recent publishing of guidance, NICE determined two oncology drugs – Pfizer’s Ibrance and AstraZeneca’s Lynparza – were promising, but for certain patient populations they should only be available through its managed-access scheme while further data is gathered. What explains this decision?
FDA grants Clovis’ Rubraca fast track designation for prostate cancer
Colorado-based Clovis Oncology has received fast track designation from the US Food and Drug Administration (FDA) for Rubraca (rucaparib) as a monotherapy for BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer (mCRPC) adult patients.
Japan approves ViiV’s two drug regimen Dovato for HIV
ViiV Healthcare’s human immunodeficiency virus (HIV) drug Dovato (dolutegravir 50mg/lamivudine 300mg) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW).
Case Study: Bristol-Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company headquartered in New York City that specialises in discovering, developing and delivering innovative medicines for patients with serious diseases.
MorphoSys and Incyte sign $900m deal for B-cell malignancies drug
Germany-based MorphoSys has announced it has signed a collaboration and license agreement with the US company Incyte to continue the global development and commercialisation of the former’s tafasitamab (MOR208) for B-cell malignancies.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.